Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers

BACKGROUND: Certolizumab pegol (CZP) is a TNF-ɑ inhibitor used to treat moderate-to-severe plaque psoriasis (PsO) in adult patients, including women of childbearing potential (WOCBP) and patients with psoriatic arthritis (PsA). There are currently limited real-world data on CZP for treatment of PsO....

Descripción completa

Detalles Bibliográficos
Autores principales: Vender, Ronald B., Lynde, Charles W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125136/
https://www.ncbi.nlm.nih.gov/pubmed/35134313
http://dx.doi.org/10.1177/12034754221078203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125136/
https://www.ncbi.nlm.nih.gov/pubmed/35134313
http://dx.doi.org/10.1177/12034754221078203

Ejemplares similares